# Pizarra — PT-pseudo_48fb60dfd22f (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_48fb60dfd22f
Task: 1

Encounter: Urology - outpatient on 14 Feb 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 24.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.986 ng/mL²
  - PSA velocity: 3.9 ng/mL/yr
  - Prior PSA: 16.9 ng/mL
  - Prostate volume: 24.35 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8596296 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Osteoarthritis
  - Problem list / PMHx: Hypertension, Osteoarthritis
  - Current medication: metoprolol, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 24 ng/mL. PI-RADS 5. PSAD 0.99. Prostate volume 24 mL. csPCa 0.86.

Vitals: weight 93 kg, height 189 cm, BMI 26.0, BP 130/73 mmHg, HR 68 bpm. Smoking: Non-smoker.

Chief complaint: Clinical reassessment sought after mpMRI acquisition and a PSA increase reaching 24.0 ng/mL.

History: A 68-year-old mechanical engineer initiated evaluation in September 2022 due to an elevated PSA reading. He is a non-smoker, and his prior biopsy bucket remains None. Long-standing hypertension is managed with metoprolol, while osteoarthritis discomfort is addressed with paracetamol taken only when necessary. He shares a home with his wife, and adult offspring stop by every week, with their son handling administrative correspondence. Moderate lower urinary tract symptoms produce an IPSS total of 12. A stable cardiology assessment occurred during autumn 2024, accompanied by routine thyroid and vascular checks. Joint stiffness limits his mobility, necessitating a walking frame for extended distances and a ground-floor consultation room. He explicitly denies unexplained weight loss, osseous pain, or nocturnal diaphoresis.

Physical examination: DRE — texture: symmetrically smooth; mobility: unrestricted; asymmetry: absent. The glandular surface presents without palpable nodules, aligning with a normal digital examination. General inspection notes a well-nourished individual in no acute distress, registering a BMI of 26.0. Hemodynamic parameters remain stable at 130/73 mmHg with a regular pulse of 68 bpm. Cardiovascular and respiratory auscultation yield unremarkable results.

Patient info: mechanical engineer; Married; Lives with partner; adult children visit weekly.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 18 units / week; exercise Running 3x/week, 5 km; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Endocrine — thyroid screening; Vascular surgery — varicose veins consult; Cardiology — annual review (stable, autumn 2024).
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.82 +/- 0.14   (95% CI 0.46-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.13  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 6.4 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=24.0, age=68.0, psad=0.986, dre_ord=0.0, vol=24.35, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used the visible panel data (PI-RADS=5, PSA=24.0, csPCa probability=0.86, DRE=Normal) and could not account for the PSA velocity (3.9 ng/mL/yr), the prior PSA (16.9 ng/mL), the PSA density (0.986 ng/mL²), or the patient's age (68).
WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability (0.82), but the guideline criterion is based only on PI-RADS $\ge 3$, which the prior correctly identified. However, the prior ignores the context that the patient is biopsy-naive and the guideline track record is based on a cohort where the PSA density and prior biopsy status are significant predictors. The prior's high confidence interval suggests the decision is robust, but it fails to account for the potential for overdiagnosis given the high csPCa probability (0.86) and the specific PSA density value.
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
laboratory panel - to see if PSA density or other lab values provide context for the PI-RADS 5 score.
previous GP / urology consultation notes - to assess the clinical suspicion level beyond the csPCa probability.
laboratory results - to see if PSA density or other lab values provide context for the PI-RADS 5 score.
GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion, and this decision is risk-adapted based on PSA density and prior biopsy status.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
mpMRI Prostate: PI-RADS 5 lesion located in the right mid-peripheral zone. Lesion size 14 x 11 x 10 mm. PSAD 0.986 ng/mL/mL. csPCa predicted probability 0.8596296.
get_psa_trend
PSA trend: Sep 2022: 11.8 ng/mL, Dec 2023: 9.8 ng/mL, Feb 2025: 24.0 ng/mL.
get_previous_notes
20 Feb 2024: Clinical review conducted during the annual health assessment. December 2023 testing recorded a PSA level of 16.9 ng/mL, reflecting a minor decline from the 17.8 ng/mL documented in September 2022.
19 Jun 2024: Subsequent discussion addressed the pending specialist consultation. Imaging data returned indicating a highly suspicious focus. Referral documentation was advanced to the urology department.
get_lab_results
PSA: 24.0 ng/mL (12 Jan 2025, H). %Free PSA: 10% (12 Jan 2025, L).

NOT RETRIEVED
The family history of prostate cancer was not retrieved, which is not required for this decision.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion located in the right mid-peripheral zone.
- PSA trend: Rising trajectory from 9.8 ng/mL (Dec 2023) to 24.0 ng/mL (Feb 2025).
- Previous notes: Imaging data returned indicating a highly suspicious focus in June 2024.

AGAINST sampling this patient now:
- mpMRI report: Lesion size 14 x 11 x 10 mm (size is noted, but context on change is missing).

WHERE THIS LEANS
The evidence strongly supports biopsy due to the PI-RADS 5 score on the MRI and the concerning PSA velocity, which aligns with the guideline criterion for biopsy when PI-RADS is 3 or higher.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the mpMRI demonstrated a PI-RADS 5 lesion, which is the primary driver according to the guideline criterion. This finding is supported by the rising PSA trajectory from 9.8 ng/mL to 24.0 ng/mL, which aligns with the statistical prior's suggestion. The decision is clear because the retrieved mpMRI report provided the necessary high-risk imaging finding to override any uncertainty.

Variables that carried weight: age=important, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
